Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development. 

Biotechnology

Health Care

Therapeutics

Tallac Therapeutics

Hong I. Wan

Kimberli Brill

Peter Dudek

Pavel Strop

Ons H.

Mark Karbarz

Janet Sim 沈彬

Em Abellana

Curtis Hecht

Bora Han

The Science and Research team at Tallac Therapeutics is dedicated to driving the discovery and preclinical development of novel immunotherapy candidates using the TRAAC platform. This team, comprising experts in clinical sciences, preclinical development, biologics discovery, and translational research, collaborates to advance the company's pipeline of TLR9 agonist-based therapies. They focus on rigorous scientific research, biomarker development, and translational strategies to ensure potent and targeted immune activation against cancer.

Science and Research

Leadership Team

Science and Research

About

Team members

Other teams at Tallac Therapeutics

Leadership Team